Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1163-1169

  Yan, Xue Dong ^a   Li, Min ^a   Yuan, Ye ^b   Mao, Ning ^b   Pan, Ling Ya ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Cell line; Cisplatin; Drug resistance; Ovarian cancer; Taxol

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MESSENGER RNA; PACLITAXEL; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RNA, MESSENGER; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 34548587400     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1163     Document Type: Article

References (26)

1. Berek JS: Epithelial ovarian cancer. In: Practical Gynecologic Oncology. Berek JS and Hacker NF (eds). Lippincott Williams & Wilkins, Philadelphia, PA, pp457, 2000.
2. Shen K: Chemotheropy in ovarian cancer. In: Challenges and Controversies in Gynecologic Oncology. Shen K and Lang JH (eds). People's Medical Publishing House, Beijing, pp99-100, 2002.
3. Vandier D, Calvez V, Massade L, Gouyette A, Mickley L, Fojo T and Rixe O: Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst 92: 642-647, 2000. (Pubitemid 30321307)
4. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
5. Liang Y, O'Driscoll L, McDonnell S, et al: Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 111: 484-493, 2004. (Pubitemid 39045313)
6. Perchellet EM, Wang Y, Weber RL, et al: Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling. Biochem Pharmacol 67: 523-537, 2004. (Pubitemid 38232892)
7. Roninson IB, Chin JE, Choi KG, et al: Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4542, 1986. (Pubitemid 16057084)
8. Whelan RD, Hosking LK, Townsend AJ, Cowan KH and Hill BT: Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun 1: 359-365, 1989.
9. Vaisman A, Varchenko M, Said I and Chaney SG: Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64, 1997. (Pubitemid 27059782)
10. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684, 1993. (Pubitemid 23328959)
11. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184, 1996. (Pubitemid 26119922)
12. Di Leo A, Bajetta E, Biganzoli L, et al: An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer 31A: 2248-2254, 1995. (Pubitemid 26050567)
13. Yang LY and Trujillo JM: Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. Cancer Res 50: 3218-3225, 1990.
14. Enns RE and Howell SB: Isolation of a gene associated with resistance to cisplatin. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (ed). Plenum Press, New York, pp213-220, 1991.
15. Twentyman PR, Fox NE, Wright KA and Bleehen NM: Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 53: 529-537, 1986. (Pubitemid 16111971)
16. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43, 2001. (Pubitemid 32530848)
17. Sangrajrang S and Fellous A: Taxol resistance. Chemotherapy 46: 327-334, 2000.
18. Dvorakova K, Payne CM, Tome ME, et al: Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther 1: 185-195, 2002.
19. Meijera C, van Luyn MJ, Nienhuis EF, Blom N, Mulder NH and de Vries EG: Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy. Biochem Pharmacol 61: 573-578, 2001. (Pubitemid 32178491)
20. Mazzoni A, Trave F, Russo P, Nicolin A and Rustum YM: Generation and characterization of a low-degree drug-resistant human tumor cell line. Oncology 47: 488-494, 1990. (Pubitemid 20379338)
21. Kolfschoten GM, Hulscher TM, Pinedo HM and Boven E: Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 83: 921-927, 2000.
22. Gottesman MM: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747-754, 1993.
23. Schondorf T, Kurbacher C, Gohring U, et al: Induction of MDR1-gene expression by antineolastic agents in ovarian cancer cell lines. Anticancer Res 22: 2199-2203, 2002. (Pubitemid 34857043)
24. Di Nicolantonio F, Knight LA, Whitehouse PA, et al: The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther 3: 1631-1637, 2004. (Pubitemid 40136719)
25. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD and Haddad BR: Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63: 8097-8102, 2003. (Pubitemid 37549452)
26. Li L, Luan Y, Wang G, et al: Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 14: 257-264, 2004.